


Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics to accelerate development timelines. Learn:… Read More

VectorY Therapeutics has announced that the first participant has been dosed in its Phase I/II PIONEER-ALS clinical trial of VTx-002 in people with amyotrophic lateral sclerosis (ALS). VTx-002 is a first-in-class vectorised antibody designed to holistically target TDP-43 pathology in ALS recently granted FDA Fast… Read More

Novartis Pharma and SciNeuro Pharmaceuticals have agreed a worldwide licensing and collaboration agreement to advance SciNeuro’s novel amyloid beta targeted antibody programme for the treatment of Alzheimer’s disease. The programme has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology… Read More

Thermal stability testing is essential in biotherapeutic development—ensuring safety, efficacy, and shelf-life. It also helps predict aggregation and guides formulation and storage decisions. Read this eBook to learn: Core techniques used in today’s labs Pros and cons of each method How to choose the right solution for your… Read More

Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. They have enjoyed considerable commercial success, particularly in treating cancer, and as a result various different types… Read More

This eBook, sponsored by Abzena, explores the latest developments in the ADC field and the opportunities presented by next generation bioconjugates.

Hosted by Drug Discovery World and sponsored by Oxford Nanopore Technologies, this webinar explores developments in CGT drug discovery and development. You will hear from Brian Culley, CEO of Lineage Cell Therapeutics, Will Decker, CSO of Diakonos Oncology, and John Maher, Scientific Founder and CSO of Leucid Bio. In… Read More

Monoclonal antibodies (mAbs), thanks to their low toxicity and high specificity, have enjoyed incredible market success across a range of disease categories. This eBook, sponsored by Evotec, examines the challenges, solutions and successes in mAb discovery and development. Download this exclusive eBook to learn more about: The 2025 scientific breakthroughs… Read More

Monoclonal antibodies (mAbs), thanks to their low toxicity and high specificity, have enjoyed incredible market success across a range of disease categories. Of the 2024 top 10 bestselling drugs, half were mAbs, with Merck’s Keytruda (pembrolizumab) in the lead, followed by Abbvie’s Humira (adalimumab), Sanofi and… Read More

New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model. The company says the findings support the continued clinical development… Read More

Delve into our case studies on ADC Synthesis, Development, and Characterization, where we reveal how: Trastuzumab-based ADCs with multiple payload linkers demonstrated specific, targeted functional activity. Flow cytometry and internalization assays confirmed antigen targeting and cellular uptake. Cytotoxicity assays revealed nanomolar IC50s only in HER2+ cell lines, confirming ADC efficacy… Read More

Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease. Amyloid beta is one of the toxic proteins which builds up in clumps… Read More

Epsilogen has completed the acquisition of TigaTx, a biotechnology company developing engineered immunoglobulin A (IgA) antibodies. As a result, US-based TigaTx will become a wholly owned subsidiary of Epsilogen. Dr Sonia Gulati, a Principal at Global BioAccess Fund, has joined the Epsilogen Board of Directors. … Read More

News round-up for 31 March – 4 April by DDW Senior Digital Content Editor Diana Spencer. The headlines this week have demonstrated the importance of antibody therapies, particularly in treating cancer, but also as potential therapeutics for a range of other diseases including hepatitis D and Alzheimer’s. Read More

Salma Jalal, Market Development Manager at Refeyn, looks at the need for and challenges of measuring antibody aggregation and discusses the ideal requirements of analytical tools to support it. Antibody therapies have cemented their place in modern healthcare, offering powerful,… Read More